Figure 2.

Characterization of therapeutic antitumor effects of HPV vaccine administered intramuscularly at different sites in a cervicovaginal tumor model. A. Schema of the experiment. Briefly, female C57BL/6 mice (five to eight weeks old, five/group) were injected with 2 × 10⁴ TC-1/luc cells at the intravaginal cavity on day 0. The mice were vaccinated with or without 20 μg/mouse of pNGVL4a-CRT/E7(detox) DNA vaccine via intramuscular (IM) injection, followed by electroporation at different sites on day 3, and subsequently boosted once five days later. The growth of cervicovaginal tumors was monitored with bioluminescence imaging. B. Bioluminescence images of the cervicovaginal TC-1/luc tumor-bearing mice. C. Bar graph depicting the mean luminescence intensity of cervicovaginal TC-1/luc tumor-bearing mice. D. Kaplan-Meier survival of the TC-1/luc tumor-bearing mice. Data are presented as mean ± SD. (*p < 0.05, ** p < 0.01, *** p < 0.001).